2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy  Shamir R. Mehta, MD, MSc, Kevin R. Bainey, MD, Warren J. Cantor, MD, Marie Lordkipanidzé, BPharm, PhD, Guillaume Marquis- Gravel, MD, Simon D. Robinson, MBChB, MD, Matthew Sibbald, MD, PhD, Derek Y. So, MD, Graham C. Wong, MD, MPH, Joseph G. Abunassar, MD, Margaret L. Ackman, PharmD, Alan D. Bell, MD, Raymond Cartier, MD, James D. Douketis, MD, Patrick R. Lawler, MD, MPH, Michael S. McMurtry, MD, Jacob A. Udell, MD, Sean van Diepen, MD, Subodh Verma, MD, G.B. John Mancini, MD, John A. Cairns, MD, Jean-François Tanguay, MD Paul W. Armstrong, MD, Akshay Bagai, MD, MHS, Claudia Bucci, PharmD, Jean-Pierre Déry, MD, Jean Diodati, MD, Jocelyn Dupuis, MD, PhD, David Fitchett, MD, Michael P. Love, MB, ChB, MRCP, MD, Robert Welsh, MD Shamir R. Mehta, MD, MSc, Kevin R. Bainey, MD, Warren J. Cantor, MD, Marie Lordkipanidzé, BPharm, PhD, Guillaume Marquis-Gravel, MD, Simon D. Robinson, MBChB, MD, Matthew Sibbald, MD, PhD, Derek Y. So, MD, Graham C. Wong, MD, MPH, Joseph G. Abunassar, MD, Margaret L. Ackman, PharmD, Alan D. Bell, MD, Raymond Cartier, MD, James D. Douketis, MD, Patrick R. Lawler, MD, MPH, Michael S. McMurtry, MD, Jacob A. Udell, MD, Sean van Diepen, MD, Subodh Verma, MD, G.B. John Mancini, MD, John A. Cairns, MD, Jean-François Tanguay, MD Paul W. Armstrong, MD, Akshay Bagai, MD, MHS, Claudia Bucci, PharmD, Jean-Pierre Déry, MD, Jean Diodati, MD, Jocelyn Dupuis, MD, PhD, David Fitchett, MD, Michael P. Love, MB, ChB, MRCP, MD, Robert Welsh, MD  Canadian Journal of Cardiology  Volume 34, Issue 3, Pages 214-233 (March 2018) DOI: 10.1016/j.cjca.2017.12.012 Copyright © 2018 Terms and Conditions

Figure 1 Recommendations for duration of DAPT in patients with ACS (STEMI or NSTEACS) who undergo PCI. ACS, acute coronary syndrome; ASA, acetylsalicylic acid; BID, twice daily; DAPT, dual antiplatelet therapy; NSAID, nonsteroidal anti-inflammatory drug; NSTEACS, non ST-segment elevation acute coronary syndrome; OAC, oral anticoagulant; OD, once daily; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, ST-segment elevation myocardial infarction. Canadian Journal of Cardiology 2018 34, 214-233DOI: (10.1016/j.cjca.2017.12.012) Copyright © 2018 Terms and Conditions

Figure 2 Recommendations for duration of DAPT in patients who undergo elective PCI. ASA, acetylsalicylic acid; BMS, bare-metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; NSAID, nonsteroidal anti-inflammatory drug; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy. Canadian Journal of Cardiology 2018 34, 214-233DOI: (10.1016/j.cjca.2017.12.012) Copyright © 2018 Terms and Conditions

Figure 3 Recommendations for patients with AF without high-risk features who undergo elective PCI. ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, acetylsalicylic acid; BID, twice daily; BMS, bare-metal stent; CCS, Canadian Cardiovascular Society; CHADS2, Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack; DES, drug-eluting stent; INR, international normalized ratio; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy. Canadian Journal of Cardiology 2018 34, 214-233DOI: (10.1016/j.cjca.2017.12.012) Copyright © 2018 Terms and Conditions

Figure 4 Recommendations for patients with AF who undergo PCI for ACS or high-risk elective PCI. ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, acetylsalicylic acid; BID, twice daily; CCS, Canadian Cardiovascular Society; CHADS2, Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack; DAPT, dual antiplatelet therapy; INR, international normalized ratio; OAC, oral anticoagulant; PCI, percutaneous coronary intervention. Canadian Journal of Cardiology 2018 34, 214-233DOI: (10.1016/j.cjca.2017.12.012) Copyright © 2018 Terms and Conditions